NextCell publishes its Interim Report 1 2022/2023

January 26, 2023

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 1 for the period September 1, 2022 – November 30, 2022 The report is available on the company’s website:
https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.

First quarter (2022-09-01 until 2022-11-30)

● Operating income amounted to 3 012 (1 347) TSEK, of which Cellaviva counted for 2 137 (1 346) TSEK.

● Operating result amounted to -8 918 (-6 472) TSEK.

● Earnings per share* amounted to -0,26 (-0,19) SEK.

● Cash and bank amounted to 88 259 (133 464) TSEK.

● Solidity**amounted to 92,0 (94,1) %.

*Earnings per share: Profit for the period divided by average number of shares. Average number of shares for the first quarter 2022/2023: 34,379,523 (34,379,523)shares. Number of shares in NextCell as of November 30, 2022: 34,379,523 (34,379,523) shares.

**Solidity: Own capital's share of the sheet total

Significant events in the first quarter

● NextCell announced in early September that the company's CEO Mathias Svahn gives a status update at Nordic Life Science days in Malmö, which is the Nordic region's largest partnering event in Life Science.

● In early October, the company published a debate article on particle in cell and gene therapy products with the International Society for Cell and Gene Therapy's Process Development, Manufacturing and Analytics Committee in the journal Cytotherapy.

● NextCell announced in mid-October that patients with type-1 diabetes that has undergone two treatments with a high dose of ProTrans cell therapy has maintained significantly higher endogenous insulin production than patients treated with low and medium dose.

● At the end of October, NextCell's CEO, Mathias Svahn, presented an update on the Company's achieved and ongoing clinical operations with the drug candidate ProTrans, which has been developed for type-1 diabetes, and other autoimmune and inflammatory diseases.

Significant events after the reporting period

● NextCell announced in mid-December that the first two adolescents in the older age cohort (12-21 years) had undergone treatment in phase II part of the paediatric diabetes study.

● The company announced in mid-January that it had received positive comments and recommendations on the proposal for paediatric plan (PIP) previously submitted to the Paediatric Unit of the European Medicines Agency (PDCO)

● NextCell announced at the end of January that it is expanding the ProTrans study in COVID-19 to the treatment of severe pneumonia caused by influenza, RS and HMP viruses.

This information is the information that NextCell Pharma AB is required to disclose under the EU Market Abuse Regulation. The information was provided by the below contact person for publication on 26^th January 2023, 07.30 CET.

For more information about NextCell Pharma AB, please contact:

Mathias Svahn, CEO

Patrik Fagerholm, CFO

Tel: +46 8-735 5595

E-mail: info@nextcellpharma.com

Website: www.nextcellpharma.com

LinkedIn: https://www.linkedin.com/company/15255207/

Twitter: https://twitter.com/NextCellPharma

Certified Adviser

‍FNCA Sweden AB is assigned as Certified Adviser, 08-528 00 399, info@fnca.se.

About NextCell Pharma AB

NextCell is a cell therapy company in clinical phase II. The company has developed a proprietary and patented platform technology to produce mesenchymal stem cells adapted for allogeneic treatment of various autoimmune and immunological diseases. The drug candidate ProTrans is now being tested for the treatment of type-1 diabetes as well as respiratory complications caused by Sars-CoV-2 infection. The focus is to take ProTrans to a market approval for type-1 diabetes via a phase III study. ProTrans is evaluated in two clinical Covid-19 studies, in Sweden and Canada. NextCell is working on completing its own GMP facility for the manufacture of ProTrans. The GMP facility is expected to be ready for manufacturing smaller quantities of ProTrans in 2023. NextCell also owns 8.5% of FamicordTX, a start-up company in CAR-T and oncology, and 100%of Cellaviva, Scandinavia's largest stem cell bank for family savings of stem cells from umbilical cord blood and umbilical cord tissue with permission from the Swedish Health and Social Care Inspectorate (IVO).

‍

Download attachment Read full press release on Cision (external link)

2017-07-31

NextCell Pharma updates on its current situation in its first quarterly report

NextCell Pharma AB (”NEXTCL”, “NextCell”) today, released its first quarterly report (April-June) since its introduction on Aktietorget. Following the issue in July, and after payment of study drug the Company has approximately SEK 20 million in cash, while the "burn rate" for the reporting period (April-June) was 3.5 MSEK (listing on Aktietorget occurred after the closing of this quarterly report). During the reporting period NextCell Pharma has recruited Leo Groenewegen, who took up the position of CFO. Besides his duties as CFO, Leo Groenewegen, together with Chairman Anders Essen-Moller,

Read more Read more

2017-07-24

NextCell Pharma AB submits clinical trial application for its drug candidate ProTrans™

NextCell Pharma AB ("NextCell") announced today that a clinical trial application for ProTrans™, a stem cell product developed with NextCell's Proprietary Selection Algorithm, has been submitted to the Medical Products Agency (Läkemedelsverket). The study is planned to evaluate the safety and efficacy of ProTrans™ in adult patients with type 1 diabetes diagnosed within two years. The study sponsor is NextCell and the principal investigator is Professor Per-Ola Carlsson, who works at Uppsala University and the Academic Hospital in Uppsala. The study will be conducted together with Karolinska

Read more Read more

2017-07-19

Disclosure notice: NextCell Pharma AB’s Chairman of the Board acquires additional shares

NextCell Pharma AB (”NextCell”) announces today, on July 19th 2017, that Chairman of the Board, Anders Essen-Möller, has acquired 263.020 shares in the company. Before the acquisition, Essen-Möller held 737.033 shares, equivalent to approximately 8.74 percent of the votes and capital. After the acquisition, Essen-Möller holds 1.000.053 shares, equivalent to approximately 11.76 percent of the votes and capital in NextCell.

Read more Read more

2017-07-13

First day of trading in stem cell company NextCell Pharma AB

NextCell Pharma AB (”NextCell”) announces today that trading with its shares and warrants of series TO 1 will commence today at the AktieTorget stock exchange. The shares will be traded under the name “NEXTCL” with the corresponding ISIN code SE009723125. The warrants will be designated with the name “NEXTCL TO 1” and ISIN code SE009888795. NextCell develops stem cell therapies, where stem cells from donated umbilical cords can treat patients who are not family of the donor. The cells are developed with NextCell's proprietary method and the company's first product, ProTrans™, is intended for

Read more Read more

NextCell publishes its Interim Report 1 2022/2023

● Operating income amounted to 3 012 (1 347) TSEK, of which Cellaviva counted for 2 137 (1 346) TSEK.

● Operating result amounted to -8 918 (-6 472) TSEK.

● Earnings per share* amounted to -0,26 (-0,19) SEK.

● Cash and bank amounted to 88 259 (133 464) TSEK.

● Solidity**amounted to 92,0 (94,1) %.

*Earnings per share: Profit for the period divided by average number of shares. Average number of shares for the first quarter 2022/2023: 34,379,523 (34,379,523)shares. Number of shares in NextCell as of November 30, 2022: 34,379,523 (34,379,523) shares.

**Solidity: Own capital's share of the sheet total

Significant events in the first quarter

● NextCell announced in early September that the company's CEO Mathias Svahn gives a status update at Nordic Life Science days in Malmö, which is the Nordic region's largest partnering event in Life Science.

● In early October, the company published a debate article on particle in cell and gene therapy products with the International Society for Cell and Gene Therapy's Process Development, Manufacturing and Analytics Committee in the journal Cytotherapy.

● NextCell announced in mid-October that patients with type-1 diabetes that has undergone two treatments with a high dose of ProTrans cell therapy has maintained significantly higher endogenous insulin production than patients treated with low and medium dose.

● At the end of October, NextCell's CEO, Mathias Svahn, presented an update on the Company's achieved and ongoing clinical operations with the drug candidate ProTrans, which has been developed for type-1 diabetes, and other autoimmune and inflammatory diseases.

Significant events after the reporting period

● NextCell announced in mid-December that the first two adolescents in the older age cohort (12-21 years) had undergone treatment in phase II part of the paediatric diabetes study.

● The company announced in mid-January that it had received positive comments and recommendations on the proposal for paediatric plan (PIP) previously submitted to the Paediatric Unit of the European Medicines Agency (PDCO)

● NextCell announced at the end of January that it is expanding the ProTrans study in COVID-19 to the treatment of severe pneumonia caused by influenza, RS and HMP viruses.

This information is the information that NextCell Pharma AB is required to disclose under the EU Market Abuse Regulation. The information was provided by the below contact person for publication on 26th January 2023, 07.30 CET.

For more information about NextCell Pharma AB, please contact:

Mathias Svahn, CEO

Patrik Fagerholm, CFO

Tel: +46 8-735 5595

E-mail: info@nextcellpharma.com

Website: www.nextcellpharma.com

LinkedIn: https://www.linkedin.com/company/15255207/

Twitter: https://twitter.com/NextCellPharma

Certified Adviser

‍FNCA Sweden AB is assigned as Certified Adviser, 08-528 00 399, info@fnca.se.

About NextCell Pharma AB

This information is the information that NextCell Pharma AB is required to disclose under the EU Market Abuse Regulation. The information was provided by the below contact person for publication on 26^th January 2023, 07.30 CET.